News
September 2024
Endobios continues the preclinical development of ENB, an innovative modulator of neuronal hyperexcitability.
The outcomes of the first service request to Neuroproof® (https://neuroproof.com) have been sent to us. We were first delighted with the preliminary plan design optimized by Olaf Schroeder, and we were impressed with the detail of the outputs. We will continue to work with (and highly recommend) Neuroproof® in the preclinical development of ENB, as well as in our future CNS drug candidates.
March 2021
Endobios has just published the first scientific manuscript related to its disruptive R&D in endosymbioses (core IP undisclosed):
“A potential third‐order role of the host endoplasmic reticulum as a contact site in interkingdom microbial endosymbiosis and viral infection”
https://sfamjournals.onlinelibrary.wiley.com/doi/10.1111/1758-2229.12938
June 2020
ENDOBIOS was shortlisted in the preselection phase of the Innovation Awards Roullier 2020, as a recognition of our proprietary method for the induction of cryptic antibiotics from microbial culturable sources (fungi, bacteria, microalgae), applicable in the agro, pharma or cosmetics industry.
June 2020
ENDOBIOS received an Innostars 2020 Award (EIT Health, European Union), as a recognition of our project related to the preclinical development of a marine-derived natural product as a drug candidate for central nervous system disorders.
https://eithealth.eu/news-article/innostars-awards-comes-back-with-its-2020-semi-finalists/
15 August 2019
ENDOBIOS is now eligible to apply for NIH grants (USA) as a foreign institution, after completing the registration procedures in the DUNS, SAM.gov, eRA Commons, Grants.gov and NATO-NCAGE systems.